Introduction {#s1}
============

Pain symptoms are extremely common in depressed patients ([@B1]), and up to 80% of patients who present in primary care settings with major depression suffer from physical symptoms such as pain ([@B2])~.~ A significant line of evidence shows increased thresholds for experimentally-induced pain (i.e., reduced perception of phasic cutaneous heat pain) in patients with major depressive disorder ([@B3], [@B4]). In other words, the "paradox of pain" in depressed individuals is manifested in decreased experimentally-induced pain sensitivity combined with a high incidence of reported endogenous pain ([@B5]). In an attempt to explain this paradox, Ward et al hypothesized that different parts of the spinothalamic tract are involved in the processing of experimental noxious stimuli vs. those that are involved in clinical pain ([@B6]). At the core of additional hypothesis in the literature ([@B7], [@B8]) is the assumption that a deficit in central pain inhibition plays an essential role in the pathophysiology of pain symptoms in depression and might explain their high incidence. Nonetheless, prior studies ([@B3], [@B9]) did not support this assumption, and failed to demonstrate decreased central pain inhibition among depressed patients when compared to healthy controls (HC). An alternative explanation is that the excessive pain symptoms among depressed patients are a result of the patients\' negative evaluation-bias in processing complex sensory input, just as is their processing pattern of facial expression and rating of future events ([@B10]).

The present study assessed the hypothesis that a unique pain processing profile typifies depressed patients and is correlated with a high incidence of pain symptoms in unipolar depression. Thus, we utilize a gold standard quantitative measure of pain processing in order to assess whether the latter is affected by a negative bias in depressed patients.

Materials and Methods {#s2}
=====================

Study Population
----------------

Depressed patients were recruited from the open ward, day admission, and outpatient clinics at the Shalvata Mental Health Center, Hod-Hasharon, Israel. Control subjects (HC) were mostly recruited from the hospital staff. All participants provided written informed consent to participate in a protocol approved by the local IRB. Participants were required to have a DSM 5 diagnosis of Major Depressive Disorder and currently be experiencing a major depressive episode (HDRS-21 total score ≥ 9). Exclusion criteria were as follows: psychotic spectrum disorders or bipolar disorder (DSM-IV criteria); chronic pain conditions or rheumatic disorders; pregnancy or lactation; agitation; drug/alcohol use 48 h prior to the study. All depressed patients were prescribed medications during the study. Most of them received a mixed regimen of antidepressants and at least one additional antidepressant, anxiolytic, or an antipsychotic/mood-stabilizer augmentation therapy (*N* = 17, 68%). Seven patients (28%) were using other psychotropic medications, without an antidepressant, at the time of the study.

Procedure
---------

All participants completed a single 3-h session. Participants completed questionnaires including demographic and clinical information, as well as undergoing a thorough clinical evaluation of their emotional and cognitive status by way of an interview and the following scales: the Hamilton Anxiety Rating Scale (HAM-A); the Mini-Mental State Examination (MMSE); the Hamilton Depression Rating scale (HDRS), the Quick Inventory of Depressive Symptoms (QIDS-SR16), and the Clinical Global Impressions (CGI) Scale to assess depression severity; and finally the Brief Symptom Inventory (BSI) and the Brief Pain Inventory (BPI) to evaluate pain symptoms and the subjective experience of pain. HAM-A, HAM-D, MMSE, and the CGI were administered by members of the study group who were qualified by an experienced senior psychiatrist. Inter-rater reliability was conducted between raters, but blinding or obligating a "minimum time of contact" was not possible in the context of the present study and its limitations. The clinical evaluation was followed by a psycho-physical test of pain parameters ([@B11], [@B12]).

TSA-II (Medoc, Ramat Yishai, Israel), a Peltier-based contact temperature stimulation device with a 30 × 30 mm^2^ contact thermode, was used to assess heat sensory threshold, heat pain threshold. Von Frey Filaments (North Coast Medical, San Jose, California) were used to determine mechanical temporal summation.

Pain-60 temperature is the temperature that induces pain ratings of 60 on a numerical pain scale of the participants\' subjective pain experience from 0 (*no pain*) to 100 (*worst pain ever*). Subjects were exposed to a series of hot stimuli of 7 s duration. The first series consisted of 45, 46, and 47°C stimulations with a 1-min inter-stimulus interval. After each stimulus, subjects were asked to verbally report the level of pain, until the stimuli that induced *pain-*60 was detected and confirmed. Pain-60 was the first noxious stimuli to be administered during the experimental session, and is considered to reflect one\'s initial processing of pain and encoding of pain intensity. CPM is designed to assess the central pain inhibition ability of the participant via the "pain inhibits pain" paradigm. CPM was performed using the TSA-II and the parallel paradigm in which the identical noxious "test stimuli" is repeated twice; one delivered before to, and then simultaneously with, a noxious "conditioning stimulus." See [Appendix 1](#SM1){ref-type="supplementary-material"} for full details on stimulation protocol and an elaborate description of all psychophysical measures of pain.

Data Analysis
-------------

Analyses were conducted using the IBM Statistical Package for Social Sciences (SPSS), Version 21. A two-tailed *p*\<*0.0*5 was considered statistically significant for all comparisons.

Independent-samples *t*-tests were used to compare the groups in the following measures: pain-60 temperature, pain threshold, sensory threshold, mechanical temporal summation, and CPM. Hierarchical linear regressions were performed in order to achieve a better understanding of the factors affecting the perception of pain. More specifically, we analyzed whether depressive symptoms could predict perception of experimental pain after controlling for possible confounders and subjective perception of pain during the study (i.e., current BPI). Separate regressions were conducted for pain measures in which DEP patients and HC significantly differed (BSI total score and pain-60 temperature). Possible predictors were entered in three blocks: (1) Two variables in which the groups differed significantly, were suspected as possible confounders. More specifically, the groups differed in education level and MMSE total score, two variables that were found to be associated with pain in earlier studies ([@B13], [@B14]). They were, therefore, entered in the first block of the regression analyses, (2) Perceived pain during the study (i.e., current BPI), and (3) depressive symptoms (i.e., HDRS total score).

Multivariate analysis of variance (MANOVA) with a between-subjects factor of *group* (DEP/HC) was used for group comparison in the BPI sub-components (mean experienced pain, current pain, and functioning). Next, the groups were compared in BSI (total score), using an independent-samples *t*-test.

Since the groups differed in education level, MMSE total score, and pain-60 temperature, the analyses were repeated using these variables as covariates (i.e., the independent-samples *t*-tests and MANOVA comparing the groups in measures of pain). The findings were almost identical to those of the original analyses and are therefore not reported.

Results {#s3}
=======

Patient Characteristics
-----------------------

Study population included twenty-five adult patients (16 females, 64%) and 25 HC (13 females, 52%), matched in age and sex. Patients had an average HDRS-21 total score of 24.08 (±5.79), and 10 of them were in the severely depressed range (HDRS-21 total score \>25). See [Table 1](#T1){ref-type="table"} for broader demographic and clinical data.

###### 

Demographic and clinical measures of depressed patients (*n* = 25) and healthy controls (*n* = 25).

  **Measures**                                                                                                **Depressed patients**   **Healthy controls**                    **Statistical analyses**
  --------------------------------------------------- ------------------------------------------------------- ------------------------ --------------------------------------- --------------------------
  Age (years) \[Mean ± SD\]                           43.6 ± 14.7                                             37.7 ± 10.6              *t*~(48)~ = 1.62, *p* = 0.111.          
  Education level (no.) \[Mean ± SD\]                 13.2 ± 4.0                                              17.1 ± 2.5               *t*~(47)~ = −3.98, *p* \< 0.001         
  Gender (male/female) \[Mean ± SD\]                  9/16                                                    12/13                    *X*${}_{(1)}^{2}$ = 0.74, *p* = 0.390   
  Age at first episode (years) \[Mean ± SD\]          29.3 ± 15.5                                             \_\_\_                   \_\_\_                                  
  Number of depressive episodes (no.) \[Mean ± SD\]   3.8 ± 2.4                                               0.0 ± 0.0                *t*~(48)~ = 7.71, *p* \< 0.001          
  Number of hospitalizations (no.) \[Mean ± SD\]      2.8 ± 2.4                                               0.0 ± 0.0                *t*~(48)~ = 5.83, *p* \< 0.001          
  HAM-D total score (no.) \[Mean ± SD\]               24.1 ± 5.8                                              1.7 ± 2.2                *t*~(48)~ = 18.06, *p* \< 0.001         
  HAM-A total score (no.) \[Mean ± SD\]               22.6 ± 7.1                                              2.3 ± 2.3                *t*~(48)~ = 13.52, *p* \< 0.001         
  CGI (no.) \[Mean ± SD\]                             5.2 ± 0.9                                               1.0 ± 0.0                *t*~(48)~ = 22.90, *p* \< 0.001         
  BSI (no.) \[Mean ± SD\]                             17.2 ± 11.3                                             3.0 ± 2.8                *t*~(47)~ = 6.10, *p* \< 0.001          
  Psychiatric medications (no. \[%\])                 Antidepressants (exclusively) \[N (%)\]                 1 (4%)                   \_\_\_                                  \_\_\_
                                                      Mixed group[^a^](#TN1){ref-type="table-fn"} \[N (%)\]   17 (68%)                 \_\_\_                                  \_\_\_
                                                      Without antidepressants \[N (%)\]                       7 (28%)                  \_\_\_                                  \_\_\_
  MMSE total score \[Mean ± SD\]                      28.2 ± 1.6                                              29.6 ± 0.6               *t*~(47)~ = −3.79, *p* \< 0.001         

*BSI, Brief Symptom Inventory; CGI, Clinical Global Impression; HAM-A, Hamilton Rating Scale for Anxiety; HAM-D, Hamilton Rating Scale for Depression; MMSE, Mini-Mental State Examination*.

*Antidepressants with combination of neuroleptics and/or mood stabilizers and/or benzodiazepines*.

Depressed patients had significantly lower pain-60 temperature scores than the HC (*p* = 0.01), indicating that their appraisal of the intensity of pain was increased in comparison to the HC (see [Table 2](#T2){ref-type="table"}).

###### 

Primary and secondary outcome measures of depressed patients (*n* = 25) and healthy controls (*n* = 25).

  **Measures**                                              **Depressed patients (mean ± SD)**   **Healthy controls (mean ± SD)**   **Statistical analyses**
  --------------------------- ----------------------------- ------------------------------------ ---------------------------------- -------------------------------------
  BPI                         Mean-experienced pain (no.)   3.2 ± 2.5                            1.9 ± 0.9                          *F*~(1,\ 45)~ = 5.90, *p* = 0.019
                              Current pain (no.)            2.9 ± 2.5                            1.2 ± 0.7                          *F*~(1,\ 45)~ = 9.55, *p* = 0.003
                              Functioning (no.)             3.9 ± 2.7                            1.3 ± 0.7                          *F*~(1,\ 45)~ = 18.95, *p* \< 0.001
  BSI (total score)           17.2 ± 11.3                   3.0 ± 2.8                            *t*~(47)~ = 6.10, *p* \< 0.001     
  Pain threshold (no.)        40.2 ± 2.4                    40.1 ± 2.4                           *t*~(48)~ = 0.08, *p* = 0.933      
  Sensory threshold (no.)     34.2 ± 1.0                    33.8 ± 0.7                           *t*~(48)~ = 1.66, *p* = 0.103      
  mTS (no.)                   1.4 ± 2.4                     1.6 ± 2.7                            *t*~(46)~ = −0.17, *p* = 0.866     
  Final CPM (no.)             6.1 ± 21.9                    6.2 ± 16.5                           *t*~(48)~ = −0.02, *p* = 0.984     
  Pain-60 temperature (no.)   43.1 ± 3.2                    45.2 ± 2.0                           *t*~(48)~ = −2.68, *p* = 0.010     
  Bath temperature (°C)       44.18 ± 0.6                   44.66 ± 0.50                         *t*~(47)~ = −3.03, *p* = 0.004     

*BPI, Brief Pain Inventory; BSI, Brief Symptom Inventory; CPM, Conditioned Pain Modulation; mTS, mechanical Temporal Summation*.

DEP patients had significantly higher scores on the BPI mean-experienced pain, and current functioning components, than did the HC, and a significantly higher BSI total scores (perceived pain during the last month). The groups did not significantly differ in the sensory threshold and pain threshold measures, as well as the mechanical temporal summation and CPM (See [Table 2](#T2){ref-type="table"}). No meaningful results were found in the linear regressions that were conducted.

No differences were found on any of the pain measures between patients taking antidepressants (exclusively or in conjunction with other medications) and patients taking other psychotropic medications. Follow-up ANOVAs indicated that patients with high HDRS-21 total scores had significantly higher scores on all BPI measures than did mildly depressed patients: BPI mean-experienced pain, *F*~(1,\ 19)~ = 4.68, *p* = 0.043; current BPI, *F*~(1,\ 19)~ = 10.19, *p* = 0.005; and BPI functioning, *F*~(1,\ 19)~ = 5.81, *p* = 0.026. Patients with higher HDRS-21 total scores also had significantly higher BSI total scores compared to DEP patients with fewer depressive symptoms, *t*~(19)~ = −3.00, *p* = 0.007.

Discussion {#s4}
==========

Our findings support the hypothesis that a unique sensory-perceptual profile differentiates patients with depression from healthy controls. Depressed patients in our sample displayed lower pain-60 temperature values compared to those manifested by HC. Thus, compared with HC, a lower temperature (weaker experimental noxious heat stimuli) led depressed patients to experience pain-60 and evaluate it as such on the numerical pain scale. A theoretical explanation for this negative bias might be based on the central role of the primary somatosensory cortex (S1) and the thalamus in human central pain processing ([@B15]). S1 has been demonstrated to be the only region whose activation magnitude significantly predicted the subjective intensity coding of noxious stimuli and correlated with subjective pain ratings. Pain-60 represents the encoding of pain intensity, and the abnormal functional connectivity between S1 and the thalamus in depressed patients ([@B16]) might explain the lower pain-60 temperature values displayed by depressed patients.

As expected, pain-60 temperature was inversely correlated with all psychopathology measures in the study Thus, the initial evaluation of pain intensity, as validated by pain-60 temperature, seems to be central in the pathophysiology of pain in depression.

The fact that other parameters of pain sensation and modulation did not differ between the groups might be explained by the fact that the heat pain stimuli used to determine pain-60 temperature was the first noxious stimuli to be administered during the experimental session. It is likely that the response to additional heat stimuli administered later was influenced by the previous noxious stimuli and did not reflect a naïve representation of pain processing. Alternatively, it is the influence of depression on the attention span to the pain stimuli ([@B17]) that accounts for this effect. More specifically, full attention is given to the initial pain stimuli (hypersensitivity), and as the participant progresses through the study protocol his/hers attention decreases and so does his sensitivity to pain. This is further supported by studies which tried to categorize depressed patients as having an affective indifference to experimental aversive stimulation, or a stoic pain behavior that underlay their putative pain insensitivity ([@B18], [@B19])~.~ Hence, we suggest that it is the pain-60 temperature that represents the unperturbed pain processing pattern in our study population.

Pain catastrophizing has emerged as one of the most robust, and reliable, psychological predictors of pain experience ([@B20]). Possibly, depressed patients\' increased evaluation of pain intensity accords with their cognitive bias, and is similar to their processing pattern of facial expression; consistent evidence demonstrates that individuals suffering from depression have a negative response bias toward sadness, so that they tend to evaluate positive (happy), neutral, or ambiguous facial expressions as sadder or less happy than do HC ([@B11], [@B21]). Combined with our results regarding pain-60 temperature, factors such as pain catastrophizing might be responsible for the cognitive-emotional bias and high incidence of pain symptoms in depressed individuals.

In our study no significant difference in terms of pain threshold and central pain inhibition but analyzing the literature and the possible reasons for that is beyond the scope of this paper.

A considerable limitation of the study is that Pain-60 is not an established test for evaluation bias, and that we did not use other tests for evaluation biases. Nonetheless, we do think that the measure of pain-50 or pain-60 temperature can potentially serve as a test for higher pain responsiveness; a recent study of our collaborators ([@B22]) demonstrated a lower Pain-50 temperature in patients with mild traumatic brain injury pain as compared with healthy controls. Thus, we believe that our finding on Pain-60 temperature as differentiating between the pain sensory-perceptual profile of patients suffering from major depression and healthy controls is not surprising.

Antidepressant medications (AD) might have an anti-nociceptive effect, and most depressed patients in our study were taking various regimens of antidepressants during the trial. Nonetheless, in a previous study, Bar et al. ([@B9]) could not show any influence of antidepressants on pain thresholds in depressed patients. Additionally, the type of pain stimulation applied can influence the results of a study such as this one, as can the physical and mental comorbidity among the study population. Finally, in the context of a brief report we could not discuss the important implications of gender differences on pain perception and modulation ([@B23]).

The present study stresses that the initial evaluation of pain intensity among depressed patients is increased compared with HC. This negative bias might affect the way pain is experienced by depressed patients and serve as a mediator between depression and pain complaints. Further studies are needed to unravel the mechanisms underlying the excessive pain symptoms reported by depressed patients.
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